title: Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction.
abstract: OBJECTIVE
  The Southwest German Interventional Study in Acute Myocardial Infarction (SIAM III) investigated potentially beneficial effects of immediate stenting after thrombolysis as opposed to a more conservative treatment regimen.
  
  
  BACKGROUND
  Treatment of acute myocardial infarction (AMI) by thrombolysis is compromised by Thrombolysis In Myocardial Infarction (TIMI) 3 flow rates of only 60% and high re-occlusion rates of the infarct-related artery (IRA). Older studies showed no benefit of coronary angioplasty after thrombolysis compared with thrombolytic therapy alone. This observation has been challenged by the superiority of primary stenting over balloon angioplasty in AMI.
  
  
  METHODS
  The SIAM III study was a multicenter, randomized, prospective, controlled trial in patients receiving thrombolysis in AMI (<12 h). Patients of group I were transferred within 6 h after thrombolysis for coronary angiography, including stenting of the IRA. Group II received elective coronary angiography two weeks after thrombolysis with stenting of the IRA.
  
  
  RESULTS
  A total of 197 patients were randomized, 163 patients fulfilled the secondary (angiographic) inclusion criteria (82 in group I, 81 in group II). Immediate stenting was associated with a significant reduction of the combined end point after six months (ischemic events, death, reinfarction, target lesion revascularization 25.6% vs. 50.6%, p = 0.001).
  
  
  CONCLUSIONS
  Immediate stenting after thrombolysis leads to a significant reduction of cardiac events compared with a more conservative approach including delayed stenting after two weeks.
authors.affiliation: Innere Medizin III, Universität des Saarlandes, Homburg/Saar, Germany. bruno.scheller@uniklinik-saarland.de
authors.forename: Bruno
authors.initials: B
authors.lastname: Scheller
authors.forename: Benno
authors.initials: B
authors.lastname: Hennen
authors.forename: Bernd
authors.initials: B
authors.lastname: Hammer
authors.forename: Jürgen
authors.initials: J
authors.lastname: Walle
authors.forename: Christian
authors.initials: C
authors.lastname: Hofer
authors.forename: Volker
authors.initials: V
authors.lastname: Hilpert
authors.forename: Horst
authors.initials: H
authors.lastname: Winter
authors.forename: Georg
authors.initials: G
authors.lastname: Nickenig
authors.forename: Michael
authors.initials: M
authors.lastname: Böhm
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D001241:Aspirin / Q000627:therapeutic use; D017023:Coronary Angiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D015607:Stents; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; C087896:reteplase; D010959:Tissue Plasminogen Activator; D001241:Aspirin